Comparison 5. HAART + pegylated liposomal doxorubicin versus HAART + liposomal daunorubicin (RCT).
Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
---|---|---|---|---|
1 Progression of KS | 1 | 46 | Risk Ratio (M-H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |